Recommendation of the President – Takhzyro (lanadelumab)

On 26 September 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 96/2024 on the evaluation of the drug Takhzyro (lanadelumab) in the drug program “Preventive treatment of patients with recurrent attacks of severe hereditary angioedema (ICD-10 D84.1)”

Publication in Public Information Bulletin (BIP) >>